Le cellule staminali nel diabete di tipo 1

Translated title of the contribution: The use of stem cells in type 1 diabetes

A. Trevisani, S. Tezza, R. di Fenza, R. Bassi, A. Farina, P. Fiorina

Research output: Contribution to journalArticle

Abstract

The use of stem cells in type 1 diabetes Type 1 diabetes (T1D) is an autoimmune disorder in which immune system attacks and destroys insulin-producing cells (β-cells) of the pancreas. Few patients have been rendered insulin-independent with actual therapies. In this review, we will discuss about the role of stem cells for the cure of T1D. An ideal treatment for T1D should preserve the remaining β-cells from an immuno-mediated destruction, restore their functionality and protect the newly generated insulin-producing cells from autoimmune response. Stem cells have immunological and regenerative properties that can either restore peripheral tolerance towards β-cells or generate new insulin producing cells. Bone marrow mesenchymal stem cells, characterized by having an hypo-immunogenic phenotype and a wide range of immunomodulatory capabilities, have shown the ability to cure new onset diabetes in NOD mice. Cord blood stem cells can give rise to islet-like clusters cells and can also facilitate the gene ration of regulatory T-cells reverting hyperglycemia in NOD mice. T1D patients, treated with cord blood stem cells, have shown a stabilization of insulin requirement and an improvement of glycometabolic control. Although hematopoietic stem cells have been used without success in mouse models, they exhibited profound immunomodulatory capacities in humans. Finally, embryonic stem cells show exciting therapeutic perspectives, thanks to their plasticity. We will review the field and curb easy enthusiasm by highlighting the problems of the field.

Original languageItalian
Pages (from-to)141-149
Number of pages9
JournalGiornale Italiano di Diabetologia e Metabolismo
Volume31
Issue number3
Publication statusPublished - Sep 2011

Fingerprint

Type 1 Diabetes Mellitus
Stem Cells
Insulin
Inbred NOD Mouse
Fetal Blood
Blood Cells
Peripheral Tolerance
Regulatory T-Lymphocytes
Embryonic Stem Cells
Hematopoietic Stem Cells
Autoimmunity
Mesenchymal Stromal Cells
Hyperglycemia
Pancreas
Immune System
Therapeutics
Bone Marrow
Phenotype
Genes

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Trevisani, A., Tezza, S., di Fenza, R., Bassi, R., Farina, A., & Fiorina, P. (2011). Le cellule staminali nel diabete di tipo 1. Giornale Italiano di Diabetologia e Metabolismo, 31(3), 141-149.

Le cellule staminali nel diabete di tipo 1. / Trevisani, A.; Tezza, S.; di Fenza, R.; Bassi, R.; Farina, A.; Fiorina, P.

In: Giornale Italiano di Diabetologia e Metabolismo, Vol. 31, No. 3, 09.2011, p. 141-149.

Research output: Contribution to journalArticle

Trevisani, A, Tezza, S, di Fenza, R, Bassi, R, Farina, A & Fiorina, P 2011, 'Le cellule staminali nel diabete di tipo 1', Giornale Italiano di Diabetologia e Metabolismo, vol. 31, no. 3, pp. 141-149.
Trevisani A, Tezza S, di Fenza R, Bassi R, Farina A, Fiorina P. Le cellule staminali nel diabete di tipo 1. Giornale Italiano di Diabetologia e Metabolismo. 2011 Sep;31(3):141-149.
Trevisani, A. ; Tezza, S. ; di Fenza, R. ; Bassi, R. ; Farina, A. ; Fiorina, P. / Le cellule staminali nel diabete di tipo 1. In: Giornale Italiano di Diabetologia e Metabolismo. 2011 ; Vol. 31, No. 3. pp. 141-149.
@article{ea65ee46d7724fada5cb9d5ad5b9c6b3,
title = "Le cellule staminali nel diabete di tipo 1",
abstract = "The use of stem cells in type 1 diabetes Type 1 diabetes (T1D) is an autoimmune disorder in which immune system attacks and destroys insulin-producing cells (β-cells) of the pancreas. Few patients have been rendered insulin-independent with actual therapies. In this review, we will discuss about the role of stem cells for the cure of T1D. An ideal treatment for T1D should preserve the remaining β-cells from an immuno-mediated destruction, restore their functionality and protect the newly generated insulin-producing cells from autoimmune response. Stem cells have immunological and regenerative properties that can either restore peripheral tolerance towards β-cells or generate new insulin producing cells. Bone marrow mesenchymal stem cells, characterized by having an hypo-immunogenic phenotype and a wide range of immunomodulatory capabilities, have shown the ability to cure new onset diabetes in NOD mice. Cord blood stem cells can give rise to islet-like clusters cells and can also facilitate the gene ration of regulatory T-cells reverting hyperglycemia in NOD mice. T1D patients, treated with cord blood stem cells, have shown a stabilization of insulin requirement and an improvement of glycometabolic control. Although hematopoietic stem cells have been used without success in mouse models, they exhibited profound immunomodulatory capacities in humans. Finally, embryonic stem cells show exciting therapeutic perspectives, thanks to their plasticity. We will review the field and curb easy enthusiasm by highlighting the problems of the field.",
keywords = "Insulin producing cells, Stem cells, Type 1 diabetes",
author = "A. Trevisani and S. Tezza and {di Fenza}, R. and R. Bassi and A. Farina and P. Fiorina",
year = "2011",
month = "9",
language = "Italian",
volume = "31",
pages = "141--149",
journal = "Giornale Italiano di Diabetologia",
issn = "1593-6104",
publisher = "UTET Periodici Scientifici srl",
number = "3",

}

TY - JOUR

T1 - Le cellule staminali nel diabete di tipo 1

AU - Trevisani, A.

AU - Tezza, S.

AU - di Fenza, R.

AU - Bassi, R.

AU - Farina, A.

AU - Fiorina, P.

PY - 2011/9

Y1 - 2011/9

N2 - The use of stem cells in type 1 diabetes Type 1 diabetes (T1D) is an autoimmune disorder in which immune system attacks and destroys insulin-producing cells (β-cells) of the pancreas. Few patients have been rendered insulin-independent with actual therapies. In this review, we will discuss about the role of stem cells for the cure of T1D. An ideal treatment for T1D should preserve the remaining β-cells from an immuno-mediated destruction, restore their functionality and protect the newly generated insulin-producing cells from autoimmune response. Stem cells have immunological and regenerative properties that can either restore peripheral tolerance towards β-cells or generate new insulin producing cells. Bone marrow mesenchymal stem cells, characterized by having an hypo-immunogenic phenotype and a wide range of immunomodulatory capabilities, have shown the ability to cure new onset diabetes in NOD mice. Cord blood stem cells can give rise to islet-like clusters cells and can also facilitate the gene ration of regulatory T-cells reverting hyperglycemia in NOD mice. T1D patients, treated with cord blood stem cells, have shown a stabilization of insulin requirement and an improvement of glycometabolic control. Although hematopoietic stem cells have been used without success in mouse models, they exhibited profound immunomodulatory capacities in humans. Finally, embryonic stem cells show exciting therapeutic perspectives, thanks to their plasticity. We will review the field and curb easy enthusiasm by highlighting the problems of the field.

AB - The use of stem cells in type 1 diabetes Type 1 diabetes (T1D) is an autoimmune disorder in which immune system attacks and destroys insulin-producing cells (β-cells) of the pancreas. Few patients have been rendered insulin-independent with actual therapies. In this review, we will discuss about the role of stem cells for the cure of T1D. An ideal treatment for T1D should preserve the remaining β-cells from an immuno-mediated destruction, restore their functionality and protect the newly generated insulin-producing cells from autoimmune response. Stem cells have immunological and regenerative properties that can either restore peripheral tolerance towards β-cells or generate new insulin producing cells. Bone marrow mesenchymal stem cells, characterized by having an hypo-immunogenic phenotype and a wide range of immunomodulatory capabilities, have shown the ability to cure new onset diabetes in NOD mice. Cord blood stem cells can give rise to islet-like clusters cells and can also facilitate the gene ration of regulatory T-cells reverting hyperglycemia in NOD mice. T1D patients, treated with cord blood stem cells, have shown a stabilization of insulin requirement and an improvement of glycometabolic control. Although hematopoietic stem cells have been used without success in mouse models, they exhibited profound immunomodulatory capacities in humans. Finally, embryonic stem cells show exciting therapeutic perspectives, thanks to their plasticity. We will review the field and curb easy enthusiasm by highlighting the problems of the field.

KW - Insulin producing cells

KW - Stem cells

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=80052981966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052981966&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:80052981966

VL - 31

SP - 141

EP - 149

JO - Giornale Italiano di Diabetologia

JF - Giornale Italiano di Diabetologia

SN - 1593-6104

IS - 3

ER -